Regional myocardial perfusion assessed with N-13 labeled ammonia and positron emission computerized axial tomography

doi:10.1016/S0002-9149(79)80006-5

The American Journal of Cardiology

Volume 43, Issue 2, February 1979, Pages 209-218

https://doi.org/10.1016/S0002-9149(79)80006-5 Get rights and content

The usefulness of N-13 ammonia as an indicator of regional myocardial perfusion suitable for positron emission tomography has been suggested. However, the relation between myocardial blood flow and uptake of N-13 ammonia has not been examined quantitatively. To quantitate the relation of myocardial N-13 ammonia tissue concentration to myocardial blood flow and examine its suitability for positron emission tomographic imaging, 12 open chest dogs were studied. In eight of the dogs, 25 imaging procedures with N-13 ammonia and positron emission tomography were performed; in the remaining four dogs the relation between flow and myocardial N-13 ammonia concentration was assessed with in vitro techniques. Positron emission tomography provided high quality cross-sectional images of the distribution of N-13 ammonia in left ventricular myocardium. No significant redistribution of N-13 ammonia in the myocardium occurred with time. Alterations in regional myocardial blood flow resulted in changes in the regional distribution of N-13 ammonia that were visible in the cross-sectional images. Myocardial N-13 ammonia concentrations measured with positron emission tomography were closely related to myocardial blood flow, although in a nonlinear fashion.

The nonlinear relation determined with positron emission tomography was identical to that observed with in vitro techniques. The nonlinearity of this relation of flow to N-13 ammonia concentration was probably due to the inverse relation between flow and the N-13 ammonia single pass extraction fraction. The uptake of N-13 ammonia was studied at myocardial blood flows ranging from 0 to 500 ml/min per 100 g, whereas physiologically occurring flows in man range only from near 0 to approximately 300 ml/min per 100 g. Within this physiologic flow range, the relation between flow and N-13 ammonia concentration was relatively linear, and a 100 percent increase in flow produced an approximately 70 percent increase in N-13 ammonia concentration.

It is concluded that N-13 ammonia is a good indicator of myocardial blood flow and compares favorably with conventional monovalent perfusion imaging agents. Positron emission computerized axial tomography permits quantitative measurements of the distribution of this agent in myocardium and therefore should prove useful in measuring regional myocardial perfusion and blood flow.

References (31)

PhelpsME
Emission computed tomography
Semin Nucl Med
(1977)
GouldKL et al.
Physiologic basis for assessing critical coronary stenosis. Instantaneous flow response and regional distribution during coronary hyperemia as measures of coronary flow reserve
Am J Cardiol
(1974)
GouldKL et al.
Noninvasive assessment of coronary stenoses by myocardial imaging during pharmacologic coronary vasodilation. II. Clinical methodology and feasibility
Am J Cardiol
(1978)
VaalburgW et al.
An improved method for the cyclotron production of ¹³N-labeled ammonia
Int J Appl Rad Isot
(1975)
HeymannMA et al.
Blood flow measurements with radionuclide-labeled particles
Prog Cardiovasc Dis
(1977)
ParkerJO et al.
The effect of nitroglycerin on coronary blood flow and the hemodynamic response to exercise in coronary artery disease
Am J Cardiol
(1971)
GouldKL et al.
Noninvasive assessment of coronary stenoses with myocardial perfusion imaging during pharmacologic coronary vasodilatation. V. Detection of 47 percent diameter coronary stenosis with intravenous nitrogen-13 ammonia and emission-computed transaxial tomography in intact dogs
Am J Cardiol
(1979)
HunterW et al.
¹³N-ammonia: A new physiologic radiotracer for molecular medicine (abstr)
J Nucl Med
(1971)
HarperPV et al.
Clinical feasibility of myocardial imaging with ¹³NH₃
J Nucl Med
(1972)
WalshWF et al.
Noninvasive evaluation of reglonal myocardial perfusion in 112 patients using a mobile scintillation camera and intravenous nitrogen-13 labeled ammonia
Circulation
(1976)

PhelpsME et al.

Tomographic images of blood pool and perfusion in brain and heart

J Nucl Med

(1976)

PhelpsME et al.

ECAT: a new computerized tomographic imaging system for positron-emitting radiopharmaceuticals

J Nucl Med

(1978)

PoeND

Comparative myocardial uptake and clearance characteristics of potassium and cesium

J Nucl Med

(1972)

MetzgerJM

Myocardial Blood Flow and Oxygen Consumption Using H₂¹⁵O and ¹⁵O-hemoglobin

RaichleME et al.

Blood brain barrier permeability of ¹¹C labeled alcohols and ¹⁵O labeled water

Am J Physiol

(1976)

Cited by (175)

Preclinical Imaging of Cardiovascular Disesase
2023, Seminars in Nuclear Medicine
Noninvasive imaging techniques, such as SPECT, PET, CT, echocardiography, or MRI, have become essential in cardiovascular research. They allow for the evaluation of biological processes in vivo without the need for invasive procedures. Nuclear imaging methods, such as SPECT and PET, offer numerous advantages, including high sensitivity, reliable quantification, and the potential for serial imaging. Modern SPECT and PET imaging systems, equipped with CT and MRI components in order to get access to morphological information with high spatial resolution, are capable of imaging a wide range of established and innovative agents in both preclinical and clinical settings. This review highlights the utility of SPECT and PET imaging as powerful tools for translational research in cardiology. By incorporating these techniques into a well-defined workflow- similar to those used in clinical imaging- the concept of “bench to bedside” can be effectively implemented.
Analysis of [<sup>11</sup>C]Choline and [<sup>13</sup>N]Ammonia using a single HPIC method
2021, Applied Radiation and Isotopes
Citation Excerpt :
[11C]Choline is a Food and Drug Administration (FDA) approved diagnostic agent for positron emission tomography (PET) imaging of biochemically recurrent prostate cancer (Grkovski et al., 2018; Hara et al., 1998). [ 13N]Ammonia is widely used as a drug for PET imaging of cardiac sarcoid (Dilsizian et al., 2016) or myocardial perfusion (Schelbert et al., 1979; Tio et al., 2009) in patients with suspected or existing coronary artery disease. As FDA approved PET drugs, quality control (QC) tests of both [11C]Choline and [13N]Ammonia include analyses of radiochemical purity, identity, chemical impurities, pH, osmolality, sterility, endotoxin, etc.
A single HPIC method was developed and validated for the analysis of both [¹¹C]Choline and [¹³N]Ammonia with the same setup. The HPIC system suitability tests were performed and [¹¹C]Choline and [¹³N]Ammonia were used to verify their performance on this HPIC method. The HPIC setup and method provides qualitative and quantitative analysis information of [¹¹C]Choline and [¹³N]Ammonia. The data suggested this HPIC method is validated for determining radiochemical/chemical purity and radiochemical identity of [¹¹C]Choline and [¹³N]Ammonia products in CGMP compliant manufacturing process.
Simplified quantification of PET myocardial blood flow: The need for technical standardization
2020, Journal of Nuclear Cardiology
Clinical PET Myocardial Perfusion Imaging and Flow Quantification
2016, Cardiology Clinics
Citation Excerpt :
PET has evolved tremendously over the last 40 years. From humble beginnings in brain imaging, limited at first to a few research centers in the 1960s and 1970s,1,2 PET has now grown to be a widely used modality in many disease areas. The development of numerous tracers imaging a wide range of biological pathways has lead to an ever-increasing reliance on PET in multiple clinical and research fields.
The coronary circulation and blood flow in left ventricular hypertrophy
2012, Journal of Molecular and Cellular Cardiology
Citation Excerpt :
These PET measurements of MBF, for which the symbol F/W is also used, have units of volume per time per unit weight of myocardium (i.e. ml/min/g) [11,16]. Different tracers can be used for measuring MBF using PET, including oxygen-15 labeled water (H215O) [17–21], 13NH3 [22–25] and the cationic potassium analog rubidium-82 (82Rb) [26,27]. 13NH3 and 82Rb are given intravenously as boluses.
Two distinct types of left ventricular hypertrophy (LVH) have been described: the so called “physiologic” hypertrophy, which is normally found in professional athletes, and “pathologic” LVH which is found in patients with inherited heart muscle disease such as hypertrophic cardiomyopathy (HCM) or patients with cardiac and systemic diseases characterized by pressure or volume overload. Patients with pathologic LVH have often symptoms and signs suggestive of myocardial ischemia despite normal coronary angiograms. Under these circumstances ischemia is due to coronary microvascular dysfunction (CMD). The abnormalities of the coronary microcirculation may be unrelated to the degree of LVH and cause a reduction in maximum myocardial blood flow which, in the absence of epicardial stenoses, is suggestive of CMD. There is no technique that enables direct visualization of coronary microcirculation in vivo in humans. Therefore, its assessment relies on the measurement of parameters which reflect its functional status, such as myocardial blood flow and coronary flow reserve which is an integrated measure of flow through both the large epicardial coronary arteries and the microcirculation. In this review article we discuss the pathophysiological mechanisms responsible for CMD in patients with primary and secondary LVH and how the recognition of this phenomenon is providing new important information on patient stratification and prognosis. Finally, we discuss how assessment of CMD may be used as a valuable surrogate marker to test the efficacy of old and new drugs. This article is part of a Special Issue entitled “Coronary Blood Flow”.
Myocardial perfusion imaging using PET/CT
2011, Medecine Nucleaire
L’étude de la perfusion myocardique par TEP a connu une expansion croissante durant les 30 dernières années. Outre ses performances supérieures à la TEMP pour le diagnostic des lésions artérielles coronaires, la TEP a prouvé sa valeur incrémentale pour la stratification pronostique des patients coronariens. L’accessibilité à la quantification absolue du débit sanguin myocardique et de la réserve de flux myocardique permet une amélioration des performances diagnostiques et constitue un marqueur indépendant de survie sans événement cardiaque. Du niveau épicardique jusqu’au niveau microvasculaire, la TEP autorise l’exploration de l’ensemble de l’arbre artériel coronaire et permet une meilleure compréhension des mécanismes physiopathologiques conduisant au développement des lésions athéromateuses. Le couplage récent à la TDM confère à la TEP-TDM un atout supplémentaire en alliant information fonctionnelle et information morphologique. L’apport respectif de ces modalités reste néanmoins à déterminer afin d’intégrer au mieux la TEP-TDM dans la prise en charge des patients atteints de cardiopathie.
For the past decade, PET and PET/CT have been widely studied for myocardial perfusion imaging. Several studies demonstrated the incremental value of PET for the diagnostic and prognostic assessment of patients with coronary artery disease. Moreover, PET allows for non-invasively quantifying myocardial blood flow and myocardial flow reserve, that both are recognized as surrogate marker of cardiac event free survival. By enabling the exploration of epicardial disease and the microvasculature, PET constitutes a unique tool to study pathophysiogical mechanisms leading to atherosclerosis genesis. The recent emergence of high-tech hybrid machines may even provide further incremental information about coronary function and morphology. By taking the best of each modality, a better assessment of patients with coronary artery disease is expected.

View all citing articles on Scopus

^*: This work was supported by Contract EY-76-C-03-0012 between the U. S. Department of Energy, Washington, D. C. and the University of California at Los Angeles.

View full text

Experimental StudyRegional myocardial perfusion assessed with N-13 labeled ammonia and positron emission computerized axial tomography*

Semin Nucl Med

Am J Cardiol

Am J Cardiol

Int J Appl Rad Isot

Prog Cardiovasc Dis

Am J Cardiol

Am J Cardiol

13N-ammonia: A new physiologic radiotracer for molecular medicine (abstr)

J Nucl Med

Clinical feasibility of myocardial imaging with 13NH3

J Nucl Med

Noninvasive evaluation of reglonal myocardial perfusion in 112 patients using a mobile scintillation camera and intravenous nitrogen-13 labeled ammonia

Circulation

Tomographic images of blood pool and perfusion in brain and heart

J Nucl Med

ECAT: a new computerized tomographic imaging system for positron-emitting radiopharmaceuticals

J Nucl Med

Comparative myocardial uptake and clearance characteristics of potassium and cesium

J Nucl Med

Myocardial Blood Flow and Oxygen Consumption Using H215O and 15O-hemoglobin

Blood brain barrier permeability of 11C labeled alcohols and 15O labeled water

Am J Physiol

Experimental Study
Regional myocardial perfusion assessed with N-13 labeled ammonia and positron emission computerized axial tomography*

¹³N-ammonia: A new physiologic radiotracer for molecular medicine (abstr)

Clinical feasibility of myocardial imaging with ¹³NH₃

Myocardial Blood Flow and Oxygen Consumption Using H₂¹⁵O and ¹⁵O-hemoglobin

Blood brain barrier permeability of ¹¹C labeled alcohols and ¹⁵O labeled water